SCHEMBL9059530

SCHEMBL9059530

CNC(=O)NSc1c(C)cccc1N1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
NPSR1 Q6W5P4 4/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
ATM Q13315 3/20 0.45
KMT2A Q03164 5/20 0.45
MEN1 O00255 4/20 0.45
LMNA P02545 3/20 0.45
ALDH1A1 P00352 5/20 0.43
POLB P06746 3/20 0.40
MAPK1 P28482 3/20 0.40
USP2 O75604 1/20 0.40
ALOX15 P16050 1/20 0.40
RAB9A P51151 1/20 0.39
TSHR P16473 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 2/20 0.39
NPC1 O15118 1/20 0.38
GFER P55789 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9060925 0.88 ALDH1A1 (0.38) MAPTNPSR1L3MBTL1ATMKMT2A
SCHEMBL9059356 0.87 AKR1C3 (0.46) MAPTNPSR1L3MBTL1KMT2AMEN1
SCHEMBL9059338 0.78 ALDH1A1 (0.42) MAPTL3MBTL1KMT2AMEN1ALDH1A1
SCHEMBL9059449 0.71 SMN1; SMN2 (0.45) L3MBTL1KMT2AMEN1LMNAALDH1A1
SCHEMBL9060475 0.70 ALDH1A1 (0.38) MAPTL3MBTL1LMNAALDH1A1RAB9A
SCHEMBL9059608 0.69 CYP2A13 (0.52) KMT2AMEN1ALOX15RAB9ASMN1; SMN2
SCHEMBL6531047 0.69 GAA (0.46) MAPTNPSR1L3MBTL1ATMKMT2A
SCHEMBL9065218 0.66 LMNA (0.68) MAPTNPSR1L3MBTL1KMT2AMEN1
SCHEMBL30228454 0.66 LMNA (0.68) MAPTNPSR1L3MBTL1KMT2AMEN1
SCHEMBL8894088 0.66 LMNA (0.68) MAPTNPSR1L3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1996017612-A1 USE OF SUBSTITUTED PHENYLAMIDINE AND PHENYLGUANIDINE COMPOUNDS FOR THE TREATMENT OF CEREBRAL AND CARDIAC ISCHAEMIA, CONVULSION AND SICKLE CELL ANAEMIA KNOLL AKTIENGESELLSCHAFT (DE) 1996-06-13 WO disclosed